First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report

BACKGROUND: We report a case of a 25-year-old male patient, who developed acquired thrombotic thrombocytopenic purpura (aTTP) after receiving a first dose of mRNA-based SARS-CoV-2 vaccine Spikevax (mRNA-1273, Moderna Biotech, USA). While this is the first case in literature describing a case of aTTP...

Descripción completa

Detalles Bibliográficos
Autores principales: Osmanodja, Bilgin, Schreiber, Adrian, Schrezenmeier, Eva, Seelow, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665311/
https://www.ncbi.nlm.nih.gov/pubmed/34895163
http://dx.doi.org/10.1186/s12882-021-02616-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665311/
https://www.ncbi.nlm.nih.gov/pubmed/34895163
http://dx.doi.org/10.1186/s12882-021-02616-3

Ejemplares similares